Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Merck (NYSE: MRK) announced that investigational sacituzumab tirumotecan (sac-TMT) met the primary overall survival endpoint in the Phase 3 TroFuse-015 trial. The trial enrolled 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma after two or more prior lines of systemic therapy. At final analysis, overall survival improved by a statistically significant margin versus physician-selected treatment, with generally consistent results regardless of TROP2 expression.
Sac-TMT did not meet the progression-free survival endpoint, which measures time until disease worsens or death. The tumor response rate favored sac-TMT but was not formally tested. No new safety signals were observed. This was the second positive Phase 3 readout from the TroFuse program. Merck plans to present the data at an upcoming medical meeting and share them with regulators.
Merck (NYSE: MRK) entered a research collaboration with Isomorphic Labs to discover small-molecule drug candidates against a cancer target. Isomorphic Labs will use its AI drug design platform and selected proprietary data from Merck to make computer-based predictions and deliver molecular designs. Merck will lead preclinical and clinical development and handle manufacturing and commercialization of any resulting products.
Merck will make an upfront payment. Isomorphic Labs is eligible for milestone payments and tiered royalties on net sales and has the option to co-fund development in exchange for higher royalties.
Merck (NYSE: MRK) named Douglas M. Baker, Jr. as its next independent lead director, effective Jan. 1, 2027.
Baker will succeed Thomas H. Glocer, who intends to retire from the board at Merck’s annual shareholder meeting in May 2027. Baker has served on the board since 2022 and previously was chairman and CEO of Ecolab.
Merck (NYSE: MRK) is discontinuing its entire BELLWAVE clinical development program evaluating nemtabrutinib for leukemia and other blood cancers. The decision follows an external Data Monitoring Committee review of the Phase 3 BELLWAVE-011 trial suggesting that benefits may not outweigh risks in that study. Merck confirmed that assessment after reviewing the data in their totality and decided to discontinue the broader program, including Phase 3 trials BELLWAVE-008 and BELLWAVE-010.
Nemtabrutinib is an investigational oral inhibitor of Bruton's tyrosine kinase, an enzyme, being evaluated for chronic lymphocytic leukemia, small lymphocytic leukemia and other blood cancers. Merck is informing trial investigators and advises patients to discuss next steps and treatment options with their study team and physician. Trial data analyses remain ongoing, and results will be shared with the scientific community.
Merck (NYSE: MRK) declared a quarterly dividend of $0.88 per common share, payable on January 8, 2027. The dividend covers the first quarter of 2027 and will be paid to shareholders of record at the close of business on December 15, 2026.
Merck (NYSE: MRK) received a positive EU regulatory committee opinion recommending expansion of ENFLONSIA to children through their second RSV season.
The proposed indication covers prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in children up to 24 months at increased risk for severe RSV disease. European Commission review is pending; Merck expects a decision in the next two months. The recommendation is supported by the Phase 3 SMART trial. ENFLONSIA already has EU approval for infants born during or entering their first RSV season. In the U.S., the FDA accepted an application for a second-season indication in eligible children under two, with a target action date of March 22, 2027.
Merck (NYSE: MRK) received a positive CHMP opinion recommending WELIREG plus lenvatinib for adults with previously treated advanced clear-cell renal cancer. The recommendation covers treatment following a PD-1 or PD-L1 inhibitor. European Commission authorization remains pending; Merck expects a final decision within two months.
In Phase 3 LITESPARK-011, the combination reduced the risk of disease progression or death by 26% versus cabozantinib, meeting the progression-free survival endpoint. Overall survival did not reach statistical significance at final analysis, despite a 15% reduction in death risk. Response rates were 53.1% versus 40.2%, and median response duration was 22.0 versus 11.9 months. The FDA approved the combination for this setting in September 2026. Trial safety findings included severe anemia, low blood oxygen and cardiac dysfunction.
Merck (NYSE: MRK) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2026. Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories, is scheduled to speak at 11:00 a.m. GMT / 6:00 a.m. ET. A live audio webcast will be available to the public.
Merck (NYSE: MRK) reported that efinopegdutide met its primary endpoint in a Phase 2b trial involving adults with MASH and liver scarring. At 52 weeks, resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening scarring occurred in 56%, 63% and 61% of participants receiving 4 mg, 7 mg and 10 mg, respectively, versus 13% with placebo; each comparison had p<0.0001.
Improvement in scarring by at least one stage without worsening steatohepatitis occurred in 43%, 52% and 34%, respectively, versus 21% with placebo. Adverse-event discontinuations were 3%, 4% and 11%, respectively, versus 1% with both placebo and open-label semaglutide. The trial enrolled 386 adults with biopsy-confirmed MASH and stage F2 or F3 scarring. Results were presented at The Liver Meeting and published in The Lancet.
Merck (NYSE: MRK) reported worldwide sales of $18.1 billion, up 5%, and narrowed its sales outlook while raising the midpoint. Its expected sales range is $66.8 billion–$67.3 billion. KEYTRUDA/KEYTRUDA QLEX sales were $8.6 billion; WINREVAIR sales rose 93% to $694 million.
Other drugmakers also reported growth: Amgen's third-quarter revenue rose 8% to $10.4 billion, Vertex's rose 12% to $3.44 billion, and Incyte's rose 14% to $1.56 billion. Gilead's product sales excluding Veklury increased 16% year over year to $8.2 billion. Gilead, Vertex and Incyte raised their full-year sales or revenue outlooks. Pricing pressures included a 14% decline in Amgen's Enbrel net selling price; Gilead expects a new Medicare price to affect Biktarvy revenue starting January 1, 2028.
The Nasdaq Biotechnology Index rose 2.1% as of 2:31 p.m. ET on November 4, alongside a broader market rally.